Basic and clinical evaluation of the efficacy of gatifloxacin in respiratory tract infections.
|
Accession number;00A0771320
|
| Title;Basic and clinical evaluation of the efficacy of gatifloxacin in respiratory tract infections. |
| Author;
OMICHI MITSUHIDE
(Hokkaido Railw. Co. JR Sapporo Hosp.)
HIRAGA YOMEI
(Hokkaido Railw. Co. JR Sapporo Hosp.)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.7;PAGE.553-560(2000)
|
| Figure&Table&Reference;FIG.1, TBL.6, REF.12 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We evaluated the fluid penetration of gatifloxacin, a new oral fluoroquinolone, and its clinical effectiveness in respiratory tract infections. 1. Concentrations in sputum and serum Gatifloxacin was orally administered to a patient with chronic bronchitis at a dose of 200 mg, twice a day, for 7 days. The concentrations of gatifloxacin in the sputum and serum were determined on the 1 st, 3 rd and 5 th days of administration. The level of gatifloxacin in the sputum exceeded that in the serum throughout the time period beginning 6 hours after the 1 st dose on the 1 st day and ending 2 hours after the 1 st dose on the 5 th day. The maximum level of gatifloxacin in the sputum during this 5-day period was 6.94 .MU.g/g, while that in the serum was 2.91 .MU.g/mL. The sputum penetration was satisfactory, with a ratio of sputum vs serum levels ranging from 1.25 to 2.38. 2. Clinical efficacy Twenty-seven patients (1 with acute bronchitis, 11 with chronic bronchitis, 5 with bacterial pneumonia, 1 with chlamydial pneumonia, 1 with mycoplasma pneumonia and 8 with infections secondary to chronic respiratory disease) were orally treated with gatifloxacin at doses of 100 to 200 mg, twice a day, for 7 to 14 days. The clinical response was excellent in 2 patients, good in 22 patients, fair in 1 patient, and poor in 2 patients. The clinical efficacy rate was 88.9%. Regarding side effects, mild epigastric distress was observed in 1 patient. Abnormal laboratory findings were observed in a total of 3 patients (one case each of an increased S-GPT, S-GOT and .GAMMA.-GTP level). The results suggest that gatifloxacin can penetrate into the sputum and is an effective antimicrobial agent for the treatment of respiratory tract infections. (author abst.) |
|
|
|
Related Articles;
|
|
